Improving infection control in nursing homes: Enhanced barrier precautions and multidrug-resistant organism colonization
American Journal of Infection Control · 2026
DOI: 10.1016/j.ajic.2026.06.013 ↗Kurz gefasst
Klinische Studie in der Zeitschrift American Journal of Infection Control, 2026. Verfasst von Mary-Claire Roghmann und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD 21201. Electronic address: mroghmann@som.umary…. Hauptthemen laut MEDLINE: Bacterial Infections, Carrier State, Cross Infection, Drug Resistance, Multiple, Bacterial. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centers for Disease Control and Prevention.
Themen: Nosokomiale Infektionen, Langzeitpflege
Abstract (Originalsprache)
BACKGROUND: Nursing home residents have a high prevalence of multidrug-resistant organism (MDRO) colonization. Centers for Disease Control and Prevention guidance recommends enhanced barrier precautions (EBP) for residents with novel or targeted MDROs and residents with indwelling medical devices or wounds, regardless of MDRO status. The guidance permits facilities to apply EBP to residents colonized with additional MDROs, as appropriate. METHODS: This study reports on prospective admission surveillance cultures collected during a trial evaluating EBP in 4 Maryland nursing homes. Our objective was to assess the effectiveness of EBP indications for identifying residents with MDRO colonization. We collected clinical characteristics and surveillance cultures from the anterior nares and inguinal skin to estimate MDRO colonization prevalence. RESULTS: Among 580 mostly short-stay residents, 31% had one or more EBP indication; 21% had a MDRO history; 13%, a medical device; and 9%, a chronic wound. Surveillance cultures detected MDRO colonization in 21% of residents. Only 1 resident had carbapenemase-producing Gram-negative bacilli; no residents had Candidozyma auris. Only 25% of residents with MDRO history were culture-positive, and 25% of MDRO-colonized by culture residents had a MDRO history. CONCLUSIONS: MDRO history was the most common indication for EBP among short-stay residents. Novel or targeted MDROs were rare, and most with MDRO history were not MDRO culture-positive. MDRO history poorly identified current MDRO-culture positive residents and may not be an effective EBP indication. GOV STUDY NUMBER: NCT03319368.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD 21201. Electronic address: mroghmann@som.umaryland.edu.
- Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD 21201.
- Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201.
Förderung
- Centers for Disease Control and Prevention
Zitieren
APA
Roghmann, M. C., O'Hara, L. M., Mayoryk, S., Robinson, G. L., Lydecker, A. D., French, I., Paszkiewicz, G., & Johnson, J. K. (2026). Improving infection control in nursing homes: Enhanced barrier precautions and multidrug-resistant organism colonization. American Journal of Infection Control. https://doi.org/10.1016/j.ajic.2026.06.013
Vancouver
Roghmann MC, O'Hara LM, Mayoryk S, Robinson GL, Lydecker AD, French I, et al. Improving infection control in nursing homes: Enhanced barrier precautions and multidrug-resistant organism colonization. American Journal of Infection Control. 2026. doi:10.1016/j.ajic.2026.06.013
BibTeX
@article{Roghmann2026,
author = {Roghmann, Mary-Claire and O'Hara, Lyndsay M and Mayoryk, Stephanie and Robinson, Gwen L and Lydecker, Alison D and French, Indira and Paszkiewicz, Gwen and Johnson, J Kristie},
title = {Improving infection control in nursing homes: Enhanced barrier precautions and multidrug-resistant organism colonization},
journal = {American Journal of Infection Control},
year = {2026},
doi = {10.1016/j.ajic.2026.06.013}
}
EUVIMED